On February 19, 2025 Tvardi Therapeutics, Inc. ("Tvardi"), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, reported that it will participate in the TD Cowen 45th Annual Health Care Conference (Press release, Tvardi Therapeutics, FEB 19, 2025, View Source [SID1234650382]). Tvardi management will host investor one-on-one investor meetings on March 3 – 5, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen’s 45th Annual Health Care Conference is taking place March 3 – 5, 2025, at the Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats, and innovative panel discussions hosted by members of the TD Cowen research team that focus on various aspects of the health care industry.